

## Zoryve<sup>™</sup> (roflumilast) – New drug approval

- On July 29, 2022, <u>Arcutis Biotherapeutics announced</u> the <u>FDA approval</u> of <u>Zoryve (roflumilast)</u>, for topical treatment of plaque psoriasis, including intertriginous areas, in patients 12 years of age and older.
- Psoriasis is a common, non-contagious, immune-mediated skin disease in which the majority of
  individuals develop "plaques," or raised, red areas of skin covered with a silver or white layer of
  dead skin cells. Psoriatic plaques are often itchy and sometimes painful and can appear on any
  area of the body.
  - Psoriasis affects approximately 9 million people in the U.S.
- Zoryve is the first topical phosphodiesterase-4 inhibitor approved for the treatment of plaque psoriasis.
- The efficacy of Zoryve was established in two randomized, double-blind, vehicle-controlled trials (DERMIS-1 and DERMIS-2) that enrolled a total of 881 subjects with mild to severe plaque psoriasis. Patients received Zoryve or vehicle applied once daily for 8 weeks. The primary endpoint was the proportion of subjects who achieved Investigator's Global Assessment (IGA) treatment success at week 8. Success was defined as a score of "Clear" (0) or "Almost Clear" (1), plus a 2-grade improvement from baseline.
  - In DERMIS-1, IGA success was seen in 41.5% of Zoryve treated patients vs. 5.8% of vehicle treated patients (Difference from vehicle: 39.7%; 95% CI: 32.4, 47.0).
  - In DERMIS-2, IGA success was seen in 36.7% of Zoryve treated patients vs. 7.1% of vehicle treated patients (Difference from vehicle: 29.5%; 95% CI: 21.5, 37.6).
- Zoryve is contraindicated in patients with moderate to severe liver impairment (Child-Pugh B or C).
- The most common adverse reactions (≥ 1%) with Zoryve use were diarrhea, headache, insomnia, application site pain, upper respiratory tract infections, and urinary tract infections.
- Zoryve should be applied to affected areas once daily and rubbed in completely.
- Arcutis Biotherapeutics plans to launch Zoryve by mid-August 2022. Zoryve will be available as a 0.3% cream in 60-gram tubes.



At Optum, we help create a healthier world, one insight, one connection, one person at a time. All Optum trademarks and logos are owned by Optum, Inc., in the U.S. and other jurisdictions. All other trademarks are the property of their respective owners. This document contains information that is considered proprietary to Optum Rx and should not be reproduced without the express written consent of Optum Rx. RxNews® is published by the Optum Rx Clinical Services Department.